See also this year's filing and all EDGAR filings for this company.
PDF Report 0001274792_2019_MERRIMACK_PHARMACEUTICALS_INC.pdf
Logs
| warning | Missing logo | subcommand.report | {} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0001274792')"} |
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss': 21, '100040 - Statement - Consolidated Statements of Operations and Comprehensive Loss2': 2}} |
Graph
Absolute values for 0001274792, MERRIMACK PHARMACEUTICALS INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 76,102,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 2,269,000 |
| 3 | remainder_Assets | 10,172,000 |
| 4 | LiabilitiesCurrent | 14,795,000 |
| 5 | LiabilitiesNoncurrent | 56,000 |
| 6 | remainder_Liabilities | 14,873,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 15,601,000 |
| 9 | ResearchAndDevelopmentExpense | 49,974,000 |
| 10 | remainder_Expenses | -7,695,000 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 17,374,000 |
| 13 | remainder_ComprehensiveNetIncome | -9,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 88,543,000 |
| 1 | Liabilities | 29,724,000 |
| 2 | Expenses | 57,880,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 58,819,000 |
| 5 | NetIncome | -40,506,000 |
| 6 | ComprehensiveNetIncome | -40,510,500 |
| 7 | BaseVar | 96,765,000 |
| 8 | EconomicCapitalRatio | 1.03 |
Edgar->Model Mapping
Feature Distribution
Change over Time
